With respect to the latter, most of HLA-A2 breast cancer patients with HER-2/neu-overexpressing tumours receiving monthly injections with the helper peptide HER-2(15369), which contains within the putative HLA-A2-binding motif HER-2(9369), developed, after immunisation, CD8 T-cell responses to peptide HER-2(9369) (10 of 15 patients tested; 66.6%) (Knutson et al, 2001). The gene discussed is ERBB2; the disease is breast carcinoma.